<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Adriamycin is the most successful <z:chebi fb="0" ids="48120">anthracycline</z:chebi> in malignant <z:hpo ids='HP_0002665'>lymphomas</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Epirubicine is too new to be fully appreciated </plain></SENT>
<SENT sid="2" pm="."><plain>Others <z:chebi fb="0" ids="48120">anthracyclines</z:chebi> have no real efficacy in nonleukemic lymphoid <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>The prognosis of malignant <z:hpo ids='HP_0002665'>lymphomas</z:hpo> has been transformed since the introduction of this drug in the chemotherapeutic protocols: the level of complete remission increased from 25% with CVP protocols to 50% with CHOP-types protocols, and to more than 70% with intensive chemotherapy protocols (m-BACOD, LNH-80) </plain></SENT>
<SENT sid="4" pm="."><plain>The number of live patients at 2 years grew in the same proportions </plain></SENT>
<SENT sid="5" pm="."><plain>The efficacy of adriamycin in follicular <z:hpo ids='HP_0002665'>lymphomas</z:hpo> is of less value </plain></SENT>
<SENT sid="6" pm="."><plain>In <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">Hodgkin's disease</z:e> the efficacy of adriamycin pull it to first line protocols (ABVD) with identical results to those obtained with MOPP chemotherapy </plain></SENT>
<SENT sid="7" pm="."><plain>This drug has its place in the treatment of <z:mp ids='MP_0009440'>myeloma</z:mp> patients and in <z:hpo ids='HP_0005550'>chronic lymphocytic leukemia</z:hpo> patients with stage C </plain></SENT>
</text></document>